Cooley’s 2022 Life Sciences M&A Year in Review
Cooley M&A
JANUARY 25, 2023
Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. With new general merger guidelines anticipated in 2023, companies should expect to see more from the agencies pushing the boundaries of traditional antitrust enforcement.
40 
Let's personalize your content